RecruitingNCT07602504

China Metastatic Liver Cancer Clinical Registry Cohort Database

Sponsor

Anhui Provincial Hospital

Enrollment

2,000 participants

Start Date

Jun 1, 2026

Study Type

OBSERVATIONAL

Conditions

Liver Cancer Liver Metastases Neoplasms Colorectal Cancer Metastatic Liver Diseases Metastases to Liver

Summary

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria4

Patients with histologically or radiologically confirmed metastatic liver cancer.
Age ≥ 18 years.
Patients who have voluntarily signed the informed consent form.
Patients with complete baseline clinical data.

Exclusion Criteria5

Patients with primary liver cancer (e.g., hepatocellular carcinoma).
Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
Patients who have previously participated in other interventional clinical trials.
Patients with severe cognitive disorders or communication barriers that prevent informed consent.
Patients with incomplete or missing key clinical data.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREStandard of Care for Metastatic Liver Cancer

In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.